Navigation Links
Southampton scientists begin Phase II patient trial for new asthma treatment
Date:4/8/2010

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

An increase in the frequency of asthma attacks (also known as 'exacerbations') is commonly triggered by cold or flu viruses because the lungs of patients with the condition are unable to mount the strong immune response that normally protects healthy airways.

When the infection spreads from the nose to the lungs it also causes inflammation which leads to such exacerbations.

A successful treatment to prevent virus-triggered asthma exacerbations would reduce the number of asthma patients suffering increased frequency of attacks and subsequently potentially life-threatening deterioration of lung function, thereby greatly reducing emergency admissions to hospital.

Professor Ratko Djukanovic, a clinical respiratory specialist at the University's School of Medicine and Southampton University Hospitals NHS Trust and Director of the Southampton Respiratory Biomedical Research Unit, explains: "When common cold or flu viruses spread from the nose and throat to the chest of asthma patients, they can cause a rapid deterioration in their health. Our scientists in Southampton, led by the team of Professor Donna Davies, have found in laboratory-based tests that the lungs are able to protect themselves when the protein interferon beta is introduced.

"If the drug works as we hope it will, it could significantly improve the quality of life for these patients and lessen the number of patients admitted to hospital. However, it is important to stress that there are a number of stages before the drug could be made available to the public.

"We are particularly pleased to have been joined in this clinical trial by other lead asthma centres in the UK which have similar biomedical research units funded by the National Institute for Health Research."

Over the next 9 - 15 months, asthma patients taking part in the study who visit the Biomedical Research Unit at Southampton General Hospital will be given either interferon beta or a placebo by inhalation, when they develop cold or flu symptoms.

The results will be used to determine if inhaled interferon beta is a viable treatment for virus-triggered asthma symptoms.

Scientists have already established that the drug was well tolerated in an earlier Phase I trial in asthma patients and that anti-viral defences were activated.

Richard Marsden, CEO of Synairgen, comments: "We are delighted to be starting this pivotal study. If these tests are successful it could lead to a new treatment being on the market in four years or so. This is very important research and showcases the best of British clinical science and interaction between industry and academic researchers."

Once the study has begun in Southampton, it will be extended to other clinical trial sites around the UK.


'/>"/>

Contact: Sophie Docker
S.Docker@soton.ac.uk
44-023-805-98933
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientists find out why living things are the size they are -- and none other
2. Scientists: Soccer improves health, fitness and social abilities
3. Pan-Asian hub for life scientists to open in Suzhou, China, on Monday, April 6
4. Scientists Find Clues to How the Body Fights Off HIV
5. Caltech scientists uncover structure of key protein in common HIV subgroup
6. Start spreading the news: NYU scientists find therapeutic target to stop cancer metastases
7. Scientists Tweak Subjects Brains to Alter Their Moral Choices
8. Scientists in hot pursuit of first new drug for global killer in 50 years
9. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
10. Anti-obesity drugs unlikely to provide lasting benefit according to scientists
11. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... PETALUMA, CA (PRWEB) , ... January 19, 2017 ... ... new Tranquility acoustic and privacy panel system. , The Tranquility privacy panel ... to a collaborative office environment. Tranquility panels help reduce noise and provide the ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top ... Cynthia Murdock and Dr. Shaun Williams have each been chosen by their peers ...
(Date:1/19/2017)... ... ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today that ... 20 years SFI has been recognized as the world’s leader in Intelligent Sales Outsourcing ... US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, Ariello, ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... lines and wrinkles. Few people know that popular cosmetic fillers can ... Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 The global  pacemaker market  is expected to ... View Research, Inc. The heightening prevalence of cardiac conditions coupled with the availability ... globally. In addition, technological enhancements in these devices are supporting the expansion of ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017  ViewRay, Inc. ... world,s first and only clinical MRI-guided radiation therapy ... proceeds of approximately $26.1 million through a private ... Capital Management led the financing and was joined ... Advisors, LLC and Kearny Venture Partners, and an ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
Breaking Medicine Technology: